Unintended consequences of glucagon-like peptide-1 receptor agonists medications in children and adolescents: A call to action

Affiliations

¹ Department of Pediatrics, School of Medicine, Institute for Clinical and Translational Science, University of California at Irvine, Irvine, CA, USA.
² University of California at Irvine, Institute for Clinical and Translational Science, Irvine, CA, USA.
³ Department of Medicine, School of Medicine, University of California at Irvine, Irvine, CA, USA.
⁴ School of Pharmacy and Pharmaceutical Sciences, University of California at Irvine, Irvine, CA, USA.
⁵ Department of Psychiatry, School of Medicine, University of California at Irvine, Irvine, CA, USA.

Editorial

Dan M Cooper et al. J Clin Transl Sci. 2023.

. 2023 Aug 18;7(1):e184.

doi: 10.1017/cts.2023.612. eCollection 2023.

¹ Department of Pediatrics, School of Medicine, Institute for Clinical and Translational Science, University of California at Irvine, Irvine, CA, USA.
² University of California at Irvine, Institute for Clinical and Translational Science, Irvine, CA, USA.
³ Department of Medicine, School of Medicine, University of California at Irvine, Irvine, CA, USA.
⁴ School of Pharmacy and Pharmaceutical Sciences, University of California at Irvine, Irvine, CA, USA.
⁵ Department of Psychiatry, School of Medicine, University of California at Irvine, Irvine, CA, USA.

No abstract available

Keywords: Pediatric; adolescent; appetite suppressant; drug abuse; eating disorders; energy expenditure; unexpected effects.

Conflict of interest statement

The authors have no conflicts of interest to declare.

1. Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-weekly semaglutide in adolescents with obesity. New Engl J Med. 2022;387(24):2245–2257. - PMC - PubMed
1. Arslanian SA, Hannon T, Zeitler P, et al. Once-weekly dulaglutide for the treatment of youths with Type 2 Diabetes. N Engl J Med. 2022;387(5):433–443. - PubMed
1. Woodard K, Louque L, Hsia DS. Medications for the treatment of obesity in adolescents. Ther Adv Endocrinol Metab. 2020;11:1–5. - PMC - PubMed
1. Saxena AR, Frias JP, Brown LS, et al. Efficacy and safety of oral small molecule glucagon-like Peptide 1 Receptor agonist danuglipron for glycemic control among patients with Type 2 Diabetes: a randomized clinical trial. JAMA Netw Open. 2023; 6(5):e2314493. - PMC - PubMed
1. Nguyen VH. School-based exercise interventions effectively increase bone mineralization in children and adolescents. Osteoporos Sarcopenia. 2018;4(2):39–46. - PMC - PubMed